A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that causes fluid-filled cysts to develop in the kidneys. The purpose of this study is to assess the safety and efficacy of ABBV-CLS-628 for the treatment of ADPKD in adult participants.
ABBV-CLS-628 is an investigational drug being developed for the treatment of ADPKD. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to placebo. Around 240 adult participants with ADPKD will be enrolled at approximately 100 sites worldwide.
Participants will receive IntraVenous ABBV-CLS-628 or placebo every 4 weeks for 92 weeks. Participants will be followed for up to 15 weeks.
There may be higher treatment burden for participants in this trial compared to their standard of care . Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Inclusion Criteria:
Exclusion Criteria:
clinicaltrialcommunication@calicolabs.com650-754-6200
Birmingham, Alabama 35294, United States
mehachem@uabmc.edu205-975-0549
Huntington Park, California 90255, United States
Los Angeles, California 90022, United States
San Francisco, California 94143-2202, United States
Santa Monica, California 90404, United States
Miami, Florida 33136, United States
Chicago, Illinois 60611-2927, United States
St Louis, Missouri 63110, United States
Chapel Hill, North Carolina 27599-0001, United States
Charleston, South Carolina 29425, United States
Chattanooga, Tennessee 37404, United States
Nashville, Tennessee 37212, United States
Toronto, Ontario M5G 2C4, Canada
Bari, Metropolitan City of Bari 70124, Italy
Rome, Roma 00168, Italy
Chiba, Chiba 260-8712, Japan
Bunkyō-Ku, Tokyo 113-8431, Japan
Dordrecht, South Holland 3318 AT, Netherlands
Daegu, Gyeongsangbuk-do 42601, South Korea
yaerim86@dsmc.or.kr+82 53-258-4740
Seoul, Seoul Teugbyeolsi 07441, South Korea
j.lai@ValianceClinicalResearch.com323-484-0508
md@amrionline.net323-725-0051
ahmadwar@hs.uci.edu714-509-6271
nicr@nicresearch.com323-725-0657
PKD@ucsf.edu415-514-1122
jessica.a.li@yale.edu203-737-1091
romani.osbourne@yale.edu203-737-1091
marie.pierrelouis@sfriresearch.com954-739-4474
rabadier@flourishresearch.com352-341-2100
schell.mia@mayo.edu904-953-3671
rperry@panaxcr.com305-698-4500
cbidot2@med.miami.edu305-243-8793
info@infigoresearch.com
frahbar@emory.edu404-727-2590
Samantha@CardioRenalInstitute.com208-996-1944
Carolina@cardiorenalinstitute.com208-984-2273
patrick.fox@northwestern.edu312-503-1887
jissele-verdinez@uiowa.edu319-384-5369
jelliott11@kumc.edu
olaniyi.ogunbodede@tuftsmedicine.org617-636-5076
nephrologyadminsupport@bidmc.harvard.edu617-632-9890
mheung@umich.edu734-936-6489
rhenschel@scsp.net313-432-6273
Helland.Ryan@mayo.edu507-422-3998
sgoldber@wustl.edu314-362-9096
212-241-2339
emily_chang@med.unc.edu919-445-2621
jrogers@brookviewhills.com336-245-6330
steph.hanzl@necresearch.org610-433-4100 ext. 490
krishna.kallem@pennmedicine.upenn.edu
simin.goral@pennmedicine.upenn.edu
research@nephassociates.com423-826-8003
tconger@knoxvillekidneycenter.com865-692-3462
swiftc@DNEPH.com214-366-6094
adel.islam@swedish.org206-215-6532
gopi.rangan@health.nsw.gov.au
martin.wolley@health.qld.gov.au+61 07 36468576
Health.RAHCNARTSClinicalTrials@sa.gov.au+61 04238 43430
Ashley.irish@health.wa.gov.au+61 08 6152 2222
jeungy0520@naver.com+82 10-6619-7204
imyongkim@gmail.com
haynepark798@hallym.or.kr